Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17292828 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175-89 17292828
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S140-p - H2AX (human)
Orthologous residues
H2AX (human): S140‑p, H2AX (mouse): S140‑p, H2AX (rat): S140‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
camptothecin increase
doxorubicin increase

S82-p - HSP27 (human)
Orthologous residues
HSP27 (human): S82‑p, HSP27 (mouse): S86‑p, HSP27 (rat): S86‑p, HSP27 (pig): S84‑p, HSP27 (hamster): S90‑p, HSP27 (chicken): S80‑p, HSP27 (dog): S86‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heat shock increase
siRNA heat shock MAPKAPK2 (human) inhibit treatment-induced increase
UCN-01 heat shock inhibit treatment-induced increase
siRNA heat shock Chk1 (human) no effect upon treatment-induced increase

T334-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): T334‑p, MAPKAPK2 (mouse): T320‑p, MAPKAPK2 (rat): T320‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
SB203580 cisplatin inhibit treatment-induced increase
siRNA cisplatin Chk1 (human) no effect upon treatment-induced increase
camptothecin increase
SB203580 camptothecin inhibit treatment-induced increase
doxorubicin increase
SB203580 doxorubicin inhibit treatment-induced increase
siRNA doxorubicin Chk1 (human) no effect upon treatment-induced increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
SB203580 cisplatin no effect upon treatment-induced increase
camptothecin increase
SB203580 camptothecin no effect upon treatment-induced increase
doxorubicin increase
SB203580 doxorubicin no effect upon treatment-induced increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
SB203580 cisplatin no effect upon treatment-induced increase
camptothecin increase
SB203580 camptothecin no effect upon treatment-induced increase
doxorubicin increase
SB203580 doxorubicin no effect upon treatment-induced increase

S345-p - Chk1 (mouse)
Orthologous residues
Chk1 (human): S345‑p, Chk1 (mouse): S345‑p, Chk1 (rat): S345‑p, Chk1 (chicken): S345‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
siRNA cisplatin MAPKAPK2 (mouse) no effect upon treatment-induced increase
doxorubicin increase
siRNA doxorubicin MAPKAPK2 (mouse) no effect upon treatment-induced increase

S140-p - H2AX (mouse)
Orthologous residues
H2AX (human): S140‑p, H2AX (mouse): S140‑p, H2AX (rat): S140‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
siRNA cisplatin MAPKAPK2 (mouse) no effect upon treatment-induced increase
doxorubicin increase
siRNA doxorubicin MAPKAPK2 (mouse) no effect upon treatment-induced increase

S11-p - H3 (mouse)
Orthologous residues
H3 (human): S11‑p, H3 (mouse): S11‑p, H3 iso2 (mouse): S11‑p, H3 iso3 (mouse): S11‑p, H3 (rat): S11‑p, H3 iso3 (rat): S11‑p, H3 (pig): S11‑p, H3 (chicken): S11‑p, H3 (cow): S11‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin decrease
siRNA cisplatin MAPKAPK2 (mouse) no effect upon treatment-induced decrease
cisplatin p53 (mouse) no effect upon treatment-induced decrease homozygous null
siRNA MAPKAPK2 (human) p53 (mouse) inhibit treatment-induced decrease
doxorubicin decrease
siRNA doxorubicin MAPKAPK2 (mouse) no effect upon treatment-induced decrease
doxorubicin p53 (mouse) no effect upon treatment-induced decrease homozygous null
siRNA MAPKAPK2 (mouse) p53 (mouse) inhibit treatment-induced decrease

T320-p - MAPKAPK2 (mouse)
Orthologous residues
MAPKAPK2 (human): T334‑p, MAPKAPK2 (mouse): T320‑p, MAPKAPK2 (rat): T320‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
doxorubicin increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.